Faculty of Medicine, Institute of Pathology, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia.
Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Head Neck Pathol. 2020 Dec;14(4):1046-1051. doi: 10.1007/s12105-020-01149-9. Epub 2020 Mar 5.
We present the historical review and current state of the histopathological classifications and terminology of laryngeal precursor lesions. Attention to recent genetic findings is also presented; although in need of additional confirmation, these raise possibility for early detection of patients at risk of dysplasia progression. Although a number of identified genetic alterations with a promising diagnostic and prognostic value are emerging, none of the known genetic alterations can be currently implemented in clinical practice as a completely reliable diagnostic and/or prognostic marker. Regarding the terminology of precursor lesions, dysplasia remains the most frequently used term, but squamous intraepithelial lesion can be used as a synonym as well. Histological findings, in spite of certain degree of subjectivity, remain at present the most reliable method for an accurate diagnosis. The current 2017 WHO classification seems to successfully stratify risk of malignant progression, with a significantly different risk of malignant progression between low-grade dysplasia and high-grade dysplasia. In case of pronounced architectural disorders, severe cellular and nuclear atypias, and an increased number of mitoses, also atypical form, the high-grade dysplasia and carcinoma in situ can be separated. The Slovenian tertiary centers have a policy of surgical removal of high-grade SILs and life-long close follow-up. Radiotherapy is reserved for more pronounced intraepithelial lesions classified as carcinoma in situ and invasive cancer. Such a distinction can facilitate clinical decision to use radiotherapy if complete surgical removal is not possible.
我们介绍了喉前体病变的组织病理学分类和术语的历史回顾和现状。还介绍了对最近遗传发现的关注;尽管需要进一步证实,但这些发现为检测有发育不良进展风险的患者提供了可能。尽管有许多具有有前途的诊断和预后价值的已识别遗传改变正在出现,但目前没有任何已知的遗传改变可以作为完全可靠的诊断和/或预后标志物应用于临床实践。关于前体病变的术语,发育不良仍然是最常用的术语,但鳞状上皮内病变也可以作为同义词使用。尽管存在一定程度的主观性,但组织学发现仍然是目前进行准确诊断的最可靠方法。目前的 2017 年 WHO 分类似乎成功地分层了恶性进展的风险,低级别发育不良和高级别发育不良之间的恶性进展风险有显著差异。在存在明显的结构紊乱、严重的细胞和核异型性以及有丝分裂增多(也包括非典型形式)时,可以将高级别发育不良和原位癌分开。斯洛文尼亚的三级中心有对高级别 SIL 进行手术切除并终身密切随访的政策。放疗保留用于更明显的上皮内病变,分类为原位癌和浸润性癌。这种区分可以促进临床决策,如果不能完全切除,则使用放疗。